{"entity":{"id":"paper-nrg-gy018-nejm-2023","kind":"paper","name":"NRG-GY018: pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer","aka":[],"tldr":"Adding pembrolizumab to carboplatin-paclitaxel and continuing it as maintenance cut the risk of progression by 70 percent in mismatch repair-deficient endometrial cancer and by 46 percent in mismatch repair-proficient disease.","summary":"Phase 3 placebo-controlled trial of 816 patients with measurable stage III to IVA, stage IVB or recurrent endometrial cancer randomised to pembrolizumab or placebo with carboplatin-paclitaxel followed by up to 14 maintenance cycles, analysed separately by mismatch repair status.\n\nIn mismatch repair-deficient disease, 12-month progression-free survival was 74 versus 38 percent (hazard ratio 0.30); in proficient disease median progression-free survival was 13.1 versus 8.7 months (hazard ratio 0.54).","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2023","url":"https://doi.org/10.1056/NEJMoa2302312"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/36972022/"}],"tags":[],"related":[],"cancers":["advanced-recurrent-endometrial-cancer","endometrial-mmr-deficient","endometrial-nsmp"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2023,"doi":"10.1056/NEJMoa2302312","pmid":"36972022","authors":"Eskander RN, Sill MW, Beffa L, et al.","paperType":"rct","findings":["Mismatch repair-deficient: progression-free survival hazard ratio 0.30.","Mismatch repair-proficient: median progression-free survival 13.1 vs 8.7 months; hazard ratio 0.54."],"whatItMeans":"Together with RUBY, this trial made chemo-immunotherapy the first-line standard for advanced endometrial cancer in both molecular groups, with the largest effect in mismatch repair-deficient tumours.","caveats":["Overall survival data were immature at first report.","Excluded carcinosarcoma, unlike RUBY."],"changedPractice":true,"participants":816},"route":"/key-papers/paper-nrg-gy018-nejm-2023/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"},{"id":"endometrial-nsmp","kind":"cancer","name":"Endometrial cancer with no specific molecular profile","route":"/cancers/endometrial-nsmp/"},{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}